

Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

| | <u>Three Months Ended</u> | |
|--|---------------------------|---------------------------|
| | <u>March 31, 2021</u> | <u>March 31, 2020</u> |
| Reconciliation of GAAP to Non-GAAP research and development: | | |
| GAAP Research and development | \$ 185,899 | \$ 169,571 |
| Less: Stock-based compensation expenses | (24,375) | (16,049) |
| Non-GAAP Research and development | <u>\$ 161,524</u> | <u>\$ 153,522</u> |
| Reconciliation of GAAP to Non-GAAP selling, general and administrative: | | |
| GAAP Selling, general and administrative | \$ 146,859 | \$ 126,761 |
| Less: Stock-based compensation expenses | (31,315) | (18,529) |
| Non-GAAP Selling, general and administrative | <u>\$ 115,544</u> | <u>\$ 108,232</u> |
| Reconciliation of GAAP to Non-GAAP operating loss: | | |
| GAAP operating loss | \$ (186,254) | \$ (210,158) |
| Add: Stock-based compensation expenses | 55,690 | 34,578 |
| Non-GAAP operating loss | <u>\$ (130,564)</u> | <u>\$ (175,580)</u> |